These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 3212781)

  • 1. Antihypertensive effect of NKY-722, a new water-soluble 1,4-dihydropyridine derivative, on conscious spontaneously hypertensive rats.
    Osumi S; Morishita S; Wada K; Usui H; Kanda M; Matsui H; Kakeya N
    Tohoku J Exp Med; 1988 Jun; 155(2):205-6. PubMed ID: 3212781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antihypertensive effect of the novel water-soluble calcium antagonist (+/-)-3-(4-allyl-1-piperazinyl)-2,2-dimethylpropyl methyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate dihydrochloride in rats.
    Wada K; Nakamura S; Morishita S; Kanda M; Matsui H; Fukata F; Shirahase H
    Arzneimittelforschung; 1994 Oct; 44(10):1112-6. PubMed ID: 7818582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of the novel water-soluble calcium antagonist (+/-)-3-(4-allyl-1-piperazinyl)-2,2-dimethylpropyl methyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate dihydrochloride on the responses of isolated canine arteries.
    Kanda M; Shirahase H; Kurahashi K; Wada K; Nakamura S; Matsui H; Fukata F
    Arzneimittelforschung; 1995 Aug; 45(8):831-5. PubMed ID: 7575741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the novel water-soluble calcium antagonist (+/-)-3-(4-allyl-1-piperazinyl)-2,2-dimethylpropyl methyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate dihydrochloride on the endothelium-independent and endothelium-dependent contraction in isolated canine cerebral arteries.
    Kanda M; Shirahase H; Wada K; Nakamura S; Matsui H; Fukata F
    Arzneimittelforschung; 1996 Jul; 46(7):663-6. PubMed ID: 8842332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antihypertensive effect of the new dihydropyridine calcium antagonist (+-)-3-(benzylmethylamino)-2,2-dimethylpropyl methyl 4-(2-fluoro-5-nitrophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedica rbo xylate hydrochloride in dogs.
    Okamiya Y; Kishimoto T; Sunakawa K; Aoki K; Tanabe H; Takeshita T; Naruchi T
    Arzneimittelforschung; 1992 Apr; 42(4):513-8. PubMed ID: 1642675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antihypertensive effect of the new calcium antagonist (+-)-3-(benzylmethylamino)-2,2-dimethylpropyl-methyl-4-(2-fluoro-5- nitrophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate hydrochloride in rats.
    Okamiya Y; Kishimoto T; Sunakawa K; Aoki K; Tanabe H; Takeshita T; Naruchi T
    Arzneimittelforschung; 1992 Jan; 42(1):9-16. PubMed ID: 1586389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antihypertensive effects of MPC-1304, a novel calcium antagonist, in experimental hypertensive rats and dogs.
    Kanda A; Haruno A; Miyake H; Nagasaka M
    J Cardiovasc Pharmacol; 1992; 20(5):723-30. PubMed ID: 1280733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antihypertensive and cardiovascular effects of the new dihydropyridine derivative methyl (E)-3-phenyl-2-propen-1-yl-1,4-dihydro-2,6-dimethyl- 4-(3-nitrophenyl)pyridine-3,5-dicarboxylate.
    Yamaura T; Kase N; Kita H; Uematsu T
    Arzneimittelforschung; 1986; 36(1):29-34. PubMed ID: 3754142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antihypertensive activity of OPC-13340, a new potent and long-acting dihydropyridine calcium antagonist, in rats.
    Nakayama N; Ikezono K; Mori T; Yamashita S; Nakayama S; Tanaka Y; Hosokawa T; Minami Y; Masutani K; Yamamura Y
    J Cardiovasc Pharmacol; 1990 May; 15(5):836-44. PubMed ID: 1692946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The receptor occupation and plasma concentration of NKY-722, a water-soluble dihydropyridine-type calcium antagonist, in spontaneously hypertensive rats.
    Uchida S; Yamada S; Ohkura T; Heshikiri M; Yoshimi A; Shirahase H; Kimura R
    Br J Pharmacol; 1995 Jan; 114(1):217-23. PubMed ID: 7712021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular activities of the new potent and long-lasting antihypertensive calcium entry blocker (+-)-3-ethyl,5-methyl,2- ([2-(formylamino)-ethyl]- thiomethyl)-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicar box ylate.
    Germini M; Passoni A; Casciarri I; Bosetti P; Piazzoni L; Cazzulani P; Gandolfi CA; Tofanetti O; Ceserani R
    Arzneimittelforschung; 1992 Jan; 42(1):1-8. PubMed ID: 1586373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of accumulation of NKY-722, a water-soluble vasoselective Ca++ antagonist, on KCl-induced contraction in isolated canine mesenteric arteries.
    Shimaji H; Shirahase H; Kanda M; Osumi S; Kurahashi K
    J Pharmacol Exp Ther; 1991 Aug; 258(2):676-80. PubMed ID: 1865364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endothelial cells modulate the vasoinhibitory effect of NKY-722, a Ca2+ channel antagonist, in canine mesenteric arteries.
    Shimaji H; Shirahase H; Kanda M; Osumi S; Kurahashi K
    Eur J Pharmacol; 1991 Apr; 196(2):197-9. PubMed ID: 1874286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological studies on a new dihydrothienopyridine calcium antagonist. 3rd communication: antihypertensive effects of S-(+)-methyl-4,7-dihydro-3-isobutyl-6-methyl-4-(3-nitrophenyl)thieno[2, 3-b] pyridine-5-carboxylate in hypertensive rats and dogs.
    Ueda M; Matsumura S; Masui M; Matsuura E; Kawakami M; Fujitomo H; Umeda T; Kagawa H; Hirohata S; Shima K
    Arzneimittelforschung; 1993 Dec; 43(12):1282-90. PubMed ID: 8141815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ramipril treatment alters Ca(2+) and K(+) channels in small mesenteric arteries from Wistar-Kyoto and spontaneously hypertensive rats.
    Cox RH; Lozinskaya I; Matsuda K; Dietz NJ
    Am J Hypertens; 2002 Oct; 15(10 Pt 1):879-90. PubMed ID: 12372675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antihypertensive effects of CS-905, a novel dihydropyridine Ca++ channel blocker.
    Oizumi K; Nishino H; Koike H; Sada T; Miyamoto M; Kimura T
    Jpn J Pharmacol; 1989 Sep; 51(1):57-64. PubMed ID: 2810942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological studies on a new dihydrothienopyridine calcium antagonist. 1st communication: comparative studies on the cardiovascular effects of methyl-4,7-dihydro-3-isobutyl-6-methyl-4-(3-nitrophenyl)thieno[2,3- b]pyridine-5-carboxylate and its two enantiomers in experimental animals.
    Ueda M; Matsumura S; Masui M; Matsuura E; Uno O; Kawakami M; Ninomiya M; Adachi I
    Arzneimittelforschung; 1993 Dec; 43(12):1270-5. PubMed ID: 8141813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vasorelaxant and antihypertensive effects of ZCM298, a dihydropyridine derivative, are through inhibiting extracellular calcium influx.
    Zhang LX; Chen XL; Yang PB; Zhang SQ; Cao YX
    Pharmacol Rep; 2013; 65(1):69-79. PubMed ID: 23563025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced myogenic response in resistance small arteries from spontaneously hypertensive rats: relationship to the voltage-dependent calcium channel.
    Shibuya J; Ohyanagi M; Iwasaki T
    Am J Hypertens; 1998 Jul; 11(7):767-73. PubMed ID: 9683036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective interaction of the calcium antagonist amlodipine with calcium channels in arteries of spontaneously hypertensive rats.
    Morel N; Godfraind T
    J Cardiovasc Pharmacol; 1994 Oct; 24(4):524-33. PubMed ID: 7528834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.